T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade

Jennifer E. Woodward, Allison L Bayer, Kenneth D. Chavin, Martin L. Blue, Prabhakar Baliga

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. T-cell activation requires engagement of the T cell receptor with the antigen-MHC and simultaneous ligation of the coreceptor CD28. CD28 binds both the CD80 (B7-1) and CD86 (B7-2) ligands on antigen-presenting cells. The functional role of these costimulatory pathways in transplantation is not completely understood. We tested the hypothesis that in vivo blockade of the CD28 pathway via the anti-CD80 and anti. CD86 monoclonal antibodies (mAbs) would prolong allograft survival. Methods. Neonatal C57BL/6J (H2b) hearts were transplanted to CBA/J (H2(k)) recipients in a heterotopic nonvascularized model, with anti-CD80 and/or anti-CD86 mAbs being administered intravenously at the time of allografting (day 0) and on the following day (day 1). Results. Anti-CD80 mAb (29.8 ±1.5 days) and anti- CD86 mAb (30.8 ± 0.5 days) alone significantly prolonged allograft survival compared with the isotype control (10.7 ± 0.4 days, P<0.01, Wilcoxon rank sum). The concurrent (days 0 and 1) and sequential administration of anti- CD86 mAb on days 0 and 1 plus anti-CD80 mAb on days 2 and 3 prolonged allograft survival to >80 days. Simultaneous administration of anti-CD80 and anti-CD86 mAbs significantly suppressed donor-specific cytotoxic T lymphocyte responses to alloantigen. Anti-CD86 mAb suppressed intragraft interleukin (IL)-4, IL-10, IL-12 p40, and IL-15 mRNA expression. Conclusions. Anti-CD80 and/or anti-CD86 mAbs are potent immunosuppressants in prolonging allograft survival. Combined blockade of the B7 (CD80 and CD86) ligands seems to be the most effective in prolonging allograft survival and suppressing donor- specific allogeneic cytotoxic T lymphocyte responses. In vivo blockade of CD86, in comparison to CD80, had the greatest immunosuppressive effect on day 7 intragraft cytokines, suggesting its role on early allogeneic immune responses.

Original languageEnglish
Pages (from-to)14-20
Number of pages7
JournalTransplantation
Volume66
Issue number1
DOIs
StatePublished - Jul 15 1998
Externally publishedYes

Fingerprint

Allografts
Monoclonal Antibodies
T-Lymphocytes
Cytotoxic T-Lymphocytes
Immunosuppressive Agents
Ligands
Interleukin-15
Isoantigens
Homologous Transplantation
Antigen-Presenting Cells
Interleukin-12
T-Cell Antigen Receptor
Interleukin-4
Interleukin-10
Ligation
Transplantation
Cytokines
Messenger RNA

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade. / Woodward, Jennifer E.; Bayer, Allison L; Chavin, Kenneth D.; Blue, Martin L.; Baliga, Prabhakar.

In: Transplantation, Vol. 66, No. 1, 15.07.1998, p. 14-20.

Research output: Contribution to journalArticle

Woodward, Jennifer E. ; Bayer, Allison L ; Chavin, Kenneth D. ; Blue, Martin L. ; Baliga, Prabhakar. / T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade. In: Transplantation. 1998 ; Vol. 66, No. 1. pp. 14-20.
@article{8bb35fbba4f14dbd9b5848e90aec0cd8,
title = "T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade",
abstract = "Background. T-cell activation requires engagement of the T cell receptor with the antigen-MHC and simultaneous ligation of the coreceptor CD28. CD28 binds both the CD80 (B7-1) and CD86 (B7-2) ligands on antigen-presenting cells. The functional role of these costimulatory pathways in transplantation is not completely understood. We tested the hypothesis that in vivo blockade of the CD28 pathway via the anti-CD80 and anti. CD86 monoclonal antibodies (mAbs) would prolong allograft survival. Methods. Neonatal C57BL/6J (H2b) hearts were transplanted to CBA/J (H2(k)) recipients in a heterotopic nonvascularized model, with anti-CD80 and/or anti-CD86 mAbs being administered intravenously at the time of allografting (day 0) and on the following day (day 1). Results. Anti-CD80 mAb (29.8 ±1.5 days) and anti- CD86 mAb (30.8 ± 0.5 days) alone significantly prolonged allograft survival compared with the isotype control (10.7 ± 0.4 days, P<0.01, Wilcoxon rank sum). The concurrent (days 0 and 1) and sequential administration of anti- CD86 mAb on days 0 and 1 plus anti-CD80 mAb on days 2 and 3 prolonged allograft survival to >80 days. Simultaneous administration of anti-CD80 and anti-CD86 mAbs significantly suppressed donor-specific cytotoxic T lymphocyte responses to alloantigen. Anti-CD86 mAb suppressed intragraft interleukin (IL)-4, IL-10, IL-12 p40, and IL-15 mRNA expression. Conclusions. Anti-CD80 and/or anti-CD86 mAbs are potent immunosuppressants in prolonging allograft survival. Combined blockade of the B7 (CD80 and CD86) ligands seems to be the most effective in prolonging allograft survival and suppressing donor- specific allogeneic cytotoxic T lymphocyte responses. In vivo blockade of CD86, in comparison to CD80, had the greatest immunosuppressive effect on day 7 intragraft cytokines, suggesting its role on early allogeneic immune responses.",
author = "Woodward, {Jennifer E.} and Bayer, {Allison L} and Chavin, {Kenneth D.} and Blue, {Martin L.} and Prabhakar Baliga",
year = "1998",
month = "7",
day = "15",
doi = "10.1097/00007890-199807150-00003",
language = "English",
volume = "66",
pages = "14--20",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade

AU - Woodward, Jennifer E.

AU - Bayer, Allison L

AU - Chavin, Kenneth D.

AU - Blue, Martin L.

AU - Baliga, Prabhakar

PY - 1998/7/15

Y1 - 1998/7/15

N2 - Background. T-cell activation requires engagement of the T cell receptor with the antigen-MHC and simultaneous ligation of the coreceptor CD28. CD28 binds both the CD80 (B7-1) and CD86 (B7-2) ligands on antigen-presenting cells. The functional role of these costimulatory pathways in transplantation is not completely understood. We tested the hypothesis that in vivo blockade of the CD28 pathway via the anti-CD80 and anti. CD86 monoclonal antibodies (mAbs) would prolong allograft survival. Methods. Neonatal C57BL/6J (H2b) hearts were transplanted to CBA/J (H2(k)) recipients in a heterotopic nonvascularized model, with anti-CD80 and/or anti-CD86 mAbs being administered intravenously at the time of allografting (day 0) and on the following day (day 1). Results. Anti-CD80 mAb (29.8 ±1.5 days) and anti- CD86 mAb (30.8 ± 0.5 days) alone significantly prolonged allograft survival compared with the isotype control (10.7 ± 0.4 days, P<0.01, Wilcoxon rank sum). The concurrent (days 0 and 1) and sequential administration of anti- CD86 mAb on days 0 and 1 plus anti-CD80 mAb on days 2 and 3 prolonged allograft survival to >80 days. Simultaneous administration of anti-CD80 and anti-CD86 mAbs significantly suppressed donor-specific cytotoxic T lymphocyte responses to alloantigen. Anti-CD86 mAb suppressed intragraft interleukin (IL)-4, IL-10, IL-12 p40, and IL-15 mRNA expression. Conclusions. Anti-CD80 and/or anti-CD86 mAbs are potent immunosuppressants in prolonging allograft survival. Combined blockade of the B7 (CD80 and CD86) ligands seems to be the most effective in prolonging allograft survival and suppressing donor- specific allogeneic cytotoxic T lymphocyte responses. In vivo blockade of CD86, in comparison to CD80, had the greatest immunosuppressive effect on day 7 intragraft cytokines, suggesting its role on early allogeneic immune responses.

AB - Background. T-cell activation requires engagement of the T cell receptor with the antigen-MHC and simultaneous ligation of the coreceptor CD28. CD28 binds both the CD80 (B7-1) and CD86 (B7-2) ligands on antigen-presenting cells. The functional role of these costimulatory pathways in transplantation is not completely understood. We tested the hypothesis that in vivo blockade of the CD28 pathway via the anti-CD80 and anti. CD86 monoclonal antibodies (mAbs) would prolong allograft survival. Methods. Neonatal C57BL/6J (H2b) hearts were transplanted to CBA/J (H2(k)) recipients in a heterotopic nonvascularized model, with anti-CD80 and/or anti-CD86 mAbs being administered intravenously at the time of allografting (day 0) and on the following day (day 1). Results. Anti-CD80 mAb (29.8 ±1.5 days) and anti- CD86 mAb (30.8 ± 0.5 days) alone significantly prolonged allograft survival compared with the isotype control (10.7 ± 0.4 days, P<0.01, Wilcoxon rank sum). The concurrent (days 0 and 1) and sequential administration of anti- CD86 mAb on days 0 and 1 plus anti-CD80 mAb on days 2 and 3 prolonged allograft survival to >80 days. Simultaneous administration of anti-CD80 and anti-CD86 mAbs significantly suppressed donor-specific cytotoxic T lymphocyte responses to alloantigen. Anti-CD86 mAb suppressed intragraft interleukin (IL)-4, IL-10, IL-12 p40, and IL-15 mRNA expression. Conclusions. Anti-CD80 and/or anti-CD86 mAbs are potent immunosuppressants in prolonging allograft survival. Combined blockade of the B7 (CD80 and CD86) ligands seems to be the most effective in prolonging allograft survival and suppressing donor- specific allogeneic cytotoxic T lymphocyte responses. In vivo blockade of CD86, in comparison to CD80, had the greatest immunosuppressive effect on day 7 intragraft cytokines, suggesting its role on early allogeneic immune responses.

UR - http://www.scopus.com/inward/record.url?scp=0032528009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032528009&partnerID=8YFLogxK

U2 - 10.1097/00007890-199807150-00003

DO - 10.1097/00007890-199807150-00003

M3 - Article

VL - 66

SP - 14

EP - 20

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -